Program
benmelstobart
Also written as “TQB2450”, “TQB2450 injection” and “Benmelstobart injection combined with Anlotinib hydrochloride capsule”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Endometrial Neoplasms · Triple Negative Breast Neoplasms · Sarcoma, Alveolar Soft Part, led by Sino Biopharmaceutical.
Drug pageBenmelstobart: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 339 open or running | phase 3since Jan 16, 2020 | Feb 26, 2018 | Dec 2027phase 3 · NCT06475599 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Feb 26, 2018.
- May 17, 2021Phase 2 study in Nasopharyngeal CarcinomaNCT04895345 · 25 enrolled · China
- Jul 13, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04964479 · 375 enrolled · China
- Nov 23, 2021Phase 3 study in Recurrent Platinum-resistant Ovarian CancerNCT05145218 · 405 enrolled · China
- Apr 20, 2022Phase 3 study in Advanced Non-squamous Non-small Cell Lung CancerNCT05346952 · 390 enrolled · China
- Nov 21, 2022Phase 2 study in Advanced Solid TumorNCT05645315 · 127 enrolled · China
- Dec 20, 2022Phase 3 study in Advanced Squamous Non-Small Cell Lung CarcinomaNCT05718167 · 570 planned · China
- Jan 19, 2023Named benmelstobartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, TQB2450
- Jun 13, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05913089 · 58 planned · China
- Oct 31, 2023Phase 1 study in Solid TumorNCT06116240 · 135 enrolled · China
- Jun 17, 20242 phase 3 studiesNCT06469879, NCT06475599
- Jul 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06496490 · 270 planned · China
- Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaNCT06767800 · 204 planned · China
- Mar 19, 2025Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06897579 · 40 enrolled · China
- Apr 17, 2026Phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177 · 33 planned · China
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
Ahead
- Dec 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT06475599
- Dec 2028Primary completion: phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177
TargetBeta
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07548177Sarcoma, Alveolar Soft Part · China | 2 | Recruiting | Dec 2028 | 33 |
| NCT06897579Extensive Stage Small Cell Lung Cancer · China | 2 | Terminated | Apr 15, 2026 | 40 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sep 2026 | 204 |
| NCT06496490Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 270 |
| NCT06475599Endometrial Neoplasms · China | 3 | Not yet recruiting | Dec 2027 | 420 |
| NCT06469879Small Cell Lung Cancer Limited Stage · China | 3 | Not yet recruiting | Sep 2026 | 358 |
| NCT06116240Solid Tumor · China | 1 | Active, not recruiting | Dec 2023 | 135 |
| NCT05913089Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 58 |
| NCT05718167Advanced Squamous Non-Small Cell Lung Carcinoma · China | 3 | Not yet recruiting | Oct 2024 | 570 |
| NCT05645315Advanced Solid Tumor · China | 2 | UNKNOWN | Dec 2023 | 127 |
| NCT05346952Advanced Non-squamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Dec 2023 | 390 |
| NCT05145218Recurrent Platinum-resistant Ovarian Cancer · China | 3 | UNKNOWN | Oct 2024 | 405 |
| NCT04964479Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 375 |
| NCT04895345Nasopharyngeal Carcinoma · China | 2 | Completed | Apr 29, 2024 | 25 |
| NCT04809142Advanced Biliary Cancer · China | 3 | UNKNOWN | Mar 18, 2022 | 392 |
| NCT04623333Recurrence · China | 2 | UNKNOWN | Dec 31, 2022 | 80 |
| NCT04574284Advanced Endometrial Cancer · China | 2 | Completed | Nov 9, 2023 | 170 |
| NCT04523272Advanced Renal Cancer · China | 3 | Active, not recruiting | Jun 2025 | 528 |
| NCT04405505Triple Negative Breast Neoplasms · China | 3 | UNKNOWN | Jul 1, 2022 | 332 |
| NCT04325763Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 315 |
| NCT04306926Advanced Oligometastatic Non-small Cell Lung Cancer · China | 2 | UNKNOWN | Oct 31, 2022 | 59 |
| NCT04236362Gynecological Cancer · China | 2 | UNKNOWN | Dec 31, 2021 | 90 |
| NCT04234607Extensive Small Cell Lung Cancer · China | 3 | UNKNOWN | Dec 2022 | 738 |
| NCT04002622Recurrence · China | 2 | Terminated | Jan 21, 2021 | 1 |
| NCT03996408Advanced Cholangiocarcinoma · China | 2 | UNKNOWN | Dec 31, 2020 | 42 |
| NCT03991975Advanced Acral Malignant Melanoma · China | 2 | UNKNOWN | Mar 31, 2020 | 42 |
| NCT03983928Lung Neoplasms · China | 2 | UNKNOWN | Oct 31, 2020 | 30 |
| NCT03910127Carcinoma, Non-Small-Cell Lung · China | 1 | UNKNOWN | Dec 31, 2020 | 90 |
| NCT03897283Advanced Solid Tumors · China | 1 | UNKNOWN | Jun 30, 2020 | 22 |
| NCT03855358Triple Negative Breast Neoplasms · China | 1 | UNKNOWN | Jun 30, 2020 | 30 |
| NCT03825705Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Jan 1, 2021 | 60 |
| NCT03800706Safety and Effectiveness · China | 2 | UNKNOWN | Jun 30, 2021 | 85 |
| NCT03460457Neoplasms | 1 | UNKNOWN | Mar 15, 2019 | 50 |
How it is read
Names in the registry
- “TQB2450”, 18 entries
- “TQB2450 injection”, 4 entries
- “Benmelstobart injection combined with Anlotinib hydrochloride capsule”, 1 entry
- “Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule”, 1 entry
- “TQB2102 for injection combined with Benmelstobart injection”, 1 entry
Codes read as this program: TQB2450.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Small Cell Lung Carcinoma, 3 studies
- Endometrial Neoplasms, 2 studies
- Triple Negative Breast Neoplasms, 2 studies
- Sarcoma, Alveolar Soft Part, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.